Overview

A Study to Investigate the Pharmacokinetics of Midazolam After Repeated Doses of Camizestrant (AZD9833) and to Investigate the Pharmacokinetics of Camizestrant When Administered Alone and in Combination With Carbamazepine in Healthy Post-Menopau

Status:
COMPLETED

Trial end date:
2025-08-20

Target enrollment:

Participant gender:

Summary

This study will be conducted in order to determine the effect of repeated oral doses of camizestrant on the pharmacokinetics (PK) of midazolam and to determine the effect of repeated oral titrated doses of carbamazepine on the PK of camizestrant in healthy post-menopausal female participants.

Phase:

PHASE1

Details

Lead Sponsor:

AstraZeneca

Treatments:

AZD9833
Carbamazepine
Midazolam